Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2017 1
2021 2
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean itziar oyarzabal[Author] (24 results)?
Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain.
Torrent A, Morgades M, García-Calduch O, de Llano MPQ, Montesinos P, Navarro I, Hernández-Rivas JM, Bárez-García A, González-Campos J, Oiartzabal I, Valero M, Cervera M, Zudaire T, Albors-Ferreiro M, López-Godino O, Gil-Cortés C, Villalón L, Saldaña R, Ribera JM. Torrent A, et al. Among authors: oiartzabal i. Eur J Haematol. 2023 Sep;111(3):485-490. doi: 10.1111/ejh.14031. Epub 2023 Jun 28. Eur J Haematol. 2023. PMID: 37381686
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies.
Tamariz-Amador LE, Battaglia AM, Maia C, Zherniakova A, Guerrero C, Zabaleta A, Burgos L, Botta C, Fortuño MA, Grande C, Manubens A, Arguiñano JM, Gomez C, Perez-Persona E, Olazabal I, Oiartzabal I, Panizo C, Prosper F, San-Miguel JF, Rodriguez-Otero P, Martín-Sánchez E, Paiva B; The Asociación Vasco-Navarra de Hematología y Hemoterapia (ASOVASNA) Cooperative Group. Tamariz-Amador LE, et al. Among authors: oiartzabal i. Blood Cancer J. 2021 Dec 14;11(12):202. doi: 10.1038/s41408-021-00594-1. Blood Cancer J. 2021. PMID: 34907159 Free PMC article.
Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice.
Montoro MJ, Pomares H, Coll R, Bernal Del Castillo T, Tormo M, Jiménez A, Brunet S, Casaño J, Oiartzabal I, Díez-Campelo M, Ramos F, Romero R, Salido-Fiérrez E, Pedro C, Bargay J, Muñoz-Novas C, López R, Rafel M, Valcárcel D; ERASME study group. Montoro MJ, et al. Among authors: oiartzabal i. Leuk Lymphoma. 2023 Mar;64(3):679-690. doi: 10.1080/10428194.2022.2154604. Epub 2022 Dec 28. Leuk Lymphoma. 2023. PMID: 36577016
Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations.
Martín I, Villamón E, Abellán R, Calasanz MJ, Irigoyen A, Sanz G, Such E, Mora E, Gutiérrez M, Collado R, García-Serra R, Vara M, Blanco ML, Oiartzabal I, Álvarez S, Bernal T, Granada I, Xicoy B, Jerez A, Calabuig M, Diez R, Gil Á, Díez-Campelo M, Solano C, Tormo M; Spanish Group of Myelodysplastic Syndromes (GESMD). Martín I, et al. Among authors: oiartzabal i. Br J Haematol. 2021 Aug;194(4):708-717. doi: 10.1111/bjh.17675. Epub 2021 Jul 22. Br J Haematol. 2021. PMID: 34296432
Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group.
Nomdedeu M, Pereira A, Calvo X, Colomer J, Sole F, Arias A, Gomez C, Luño E, Cervera J, Arnan M, Pomares H, Ramos F, Oiartzabal I, Espinet B, Pedro C, Arrizabalaga B, Blanco ML, Tormo M, Hernandez-Rivas JM, Díez-Campelo M, Ortega M, Valcárcel D, Cedena MT, Collado R, Grau J, Granada I, Sanz G, Campo E, Esteve J, Costa D; Spanish MDS Group. Nomdedeu M, et al. Among authors: oiartzabal i. Leuk Res. 2017 Dec;63:85-89. doi: 10.1016/j.leukres.2017.10.011. Epub 2017 Oct 28. Leuk Res. 2017. PMID: 29121539
[Transfusional independence in a patient with refractory anemia with excess blasts-2 refractory to 5-azacitidine treated with deferasirox and colony stimulating factors].
Moreno de Gusmão B, Guinea de Castro JM, Perez-Persona E, Oiartzabal I. Moreno de Gusmão B, et al. Among authors: oiartzabal i. Med Clin (Barc). 2014 Jan 21;142(2):91-2. doi: 10.1016/j.medcli.2013.04.023. Epub 2013 Jun 20. Med Clin (Barc). 2014. PMID: 23790532 Spanish. No abstract available.